Bladder Instillation Composition with pH Buffer for Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for interstitial cystitis lack effectiveness and stability, with existing compositions exhibiting poor storage stability and variable efficacy, often leading to the use of degraded products that can be harmful and reduce treatment success.
Innovation Solution
A pharmaceutical composition containing chondroitin sulfate, hyaluronic acid, and a phosphate buffer system, optimized to maintain a pH between 6.1 and 7.9, which enhances storage stability and efficacy by forming a stable matrix that prevents degradation of active ingredients.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If existing compositions for treating interstitial cystitis are used, then treatment is provided, but storage stability is poor and active ingredients degrade
Solution Approach 1:
The patent applies parameter changes by optimizing the pH range (6.1-7.9) and specific concentrations of chondroitin sulfate (20 mg/ml) and hyaluronic acid (16 mg/ml) to enhance storage stability and prevent degradation of active ingredients during storage
Solution Approach 2:
The patent uses a composite material approach by combining chondroitin sulfate and hyaluronic acid in specific ratios within a phosphate buffer system, creating a synergistic formulation that improves both storage stability and therapeutic efficacy compared to single-ingredient compositions
2Duration of action of stationary object
If existing compositions are stored over time, then storage is possible, but active ingredient concentrations decrease and harmful degradation products form
Solution Approach 1:
The patent applies preliminary anti-action by incorporating a phosphate buffer system that proactively maintains pH within the optimal range (6.1-7.9), preventing the chemical conditions that would lead to degradation of chondroitin sulfate and hyaluronic acid before degradation can occur
Solution Approach 2:
The patent optimizes concentration parameters and pH control to stabilize the composition during storage, preventing the formation of harmful degradation products while maintaining high active ingredient concentrations over extended storage periods
Data Source
AI summary
The invention relates to a composition, in particular a pharmaceutical composition, which is suitable in particular for the prophylactic and/or therapeutic treatment preferably of inflammatory diseases of the urogenital tract, in particular inflammatory diseases of the bladder, preferably cystitis, to the uses thereof, to a storage or application device relating to same, to a packaging unit, and finally to a kit which is designed in particular as an instillation system.